查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1874529

全球眼科藥品市場

Ophthalmic Pharmaceutical Drugs
出版日期: | 出版商: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 英文 272 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到2030年，全球眼科藥品市場規模將達到1,025億美元。

2024年全球眼科藥品市場規模估計為830億美元，預計到2030年將達到1025億美元，在分析期（2024-2030年）內複合年成長率（CAGR）為3.6%。本報告分析的細分市場之一—抗VEGF藥物，預計將以4.4%的複合年成長率成長，並在分析期結束時達到343億美元。抗青光眼藥物細分市場預計在分析期間將以2.7%的複合年成長率成長。

美國市場規模估計為221億美元，而中國市場預計將以6.3%的複合年成長率成長。

據估計，2024年美國眼科藥品市場規模將達221億美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到214億美元，在2024年至2030年的分析期間內，複合年成長率（CAGR）為6.3%。其他值得關注的區域市場分析包括日本和加拿大，預計在分析期間內，兩國的複合年成長率分別為0.7%和4.3%。在歐洲，德國的複合年成長率預計約為1.6%。

全球眼科藥品市場－主要市場趨勢與促進因素概述

什麼是眼科藥物？它們為什麼重要？

眼科藥物是專門用於治療各種眼部疾病和病症的藥物，包括青光眼、乾眼症、感染疾病和發炎性疾病。這些藥物設計用於直接給藥於眼部，從而實現標靶治療，最大限度地減少全身暴露，進而降低副作用。眼科藥物包括抗生素、抗真菌藥物和抗發炎藥，以及用於治療慢性疾病（例如老齡化黃斑部病變(AMD) 和糖尿病視網膜病變）的藥物。隨著全球眼科疾病率的不斷上升，這些藥物在保護視力、提高眼科疾病患者的生活品質方面發揮著至關重要的作用。

醫學研究的進展對眼科藥物領域有何影響？

醫學研究的進步顯著推動了新型高效眼科藥物的研發。近年來，我們對主要眼科疾病生理機制的理解不斷加深，促使人們研發出針對特定分子路徑、標靶治療這些疾病的創新藥物。例如，抗血管內皮生長因子（VEGF）療法透過抑制視網膜異常血管的生長，徹底改變了老齡化黃斑部病變（AMD）和糖尿病黃斑部水腫等疾病的治療。此外，緩釋性植入和奈米技術等藥物傳遞技術的進步，透過促進藥物吸收和延長作用時間，提高了治療效果，這對於需要長期管理的慢性疾病尤其重要。

哪些趨勢正在推動眼科製藥產業的發展？

推動眼科製藥產業發展的幾個關鍵趨勢是其中之一。全球人口老化是主要因素，老年人罹患多種眼科疾病的風險較高，包括青光眼和老齡化黃斑部病變。這種人口結構變化增加了對眼科治療的需求，並推動了市場成長。此外，人們越來越偏好微創治療，這促進了先進藥物輸送系統的發展，為傳統手術提供了替代方案。隨著全球糖尿病盛行率的上升，糖尿病視網膜病變的發生率也在增加，進一步提高了對有效治療方法的需求。此外，人們對眼科疾病的認知不斷提高，診斷技術的進步使得眼科疾病的早期發現和治療成為可能，這也進一步推動了對眼科製藥的需求。

哪些因素正在推動眼科藥品市場的成長？

眼科藥品市場的成長受多種因素驅動，包括藥物研發和給藥系統技術的進步，這些進步提高了治療效果和患者依從性。全球老年人口的成長（老年人易患慢性眼科疾病）顯著推動了眼科藥品需求的成長。此外，糖尿病等慢性疾病在全球範圍內的日益增多（這些疾病常伴隨嚴重的眼部併發症）也促進了市場成長。消費者行為的改變促使他們傾向於選擇更先進、創傷更小、恢復更快、副作用更少的治療方法，意識提升，在市場擴張中發揮關鍵作用，確保了對這些重要藥物的持續需求。

部分：

藥物分類（抗 VEGF 藥物、抗青光眼藥物、抗發炎藥物、抗過敏藥物、其他藥物分類）、類型（處方藥、非處方藥）

受訪公司範例

  • Allergan PLC
  • Bayer AG
  • F. Hoffmann-La Roche AG
  • Johnson and Johnson Vision Care Inc
  • Kyowa Kirin Co., Ltd
  • Novartis International AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Santen Pharmaceuticals Co., Ltd.
  • Shire PLC

人工智慧整合

我們正在利用檢驗的專家內容和人工智慧工具，改變您分析市場和競爭情報的方式。

Global Industry Analysts 沒有依賴查詢通用 LLM（大規模語言模型）或產業專用的SLM（小規模語言模型），而是建立了一個由世界各地領域專家精心策劃的內容庫，其中包括影片轉錄、BLOG、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

我們最新發布的報告納入了關稅對區域市場的影響，正如全球產業分析師預測的那樣，關稅將改變企業的競爭地位，而企業的競爭地位將取決於其總部所在地、製造地以及進出口（成品和OEM產品）。這種複雜多變的市場現實將透過微觀和宏觀市場動態影響競爭對手，包括銷貨成本增加、盈利下降以及供應鏈重組。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 亞太其他地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 競賽

簡介目錄
Product Code: MCP-1490

Global Ophthalmic Pharmaceutical Drugs Market to Reach US$102.5 Billion by 2030

The global market for Ophthalmic Pharmaceutical Drugs estimated at US$83.0 Billion in the year 2024, is expected to reach US$102.5 Billion by 2030, growing at a CAGR of 3.6% over the analysis period 2024-2030. Anti-VEGF Agents, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$34.3 Billion by the end of the analysis period. Growth in the Anti-Glaucoma segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$22.1 Billion While China is Forecast to Grow at 6.3% CAGR

The Ophthalmic Pharmaceutical Drugs market in the U.S. is estimated at US$22.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$21.4 Billion by the year 2030 trailing a CAGR of 6.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.7% and 4.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Ophthalmic Pharmaceutical Drugs Market - Key Trends & Drivers Summarized

What Are Ophthalmic Pharmaceutical Drugs and Why Are They Important?

Ophthalmic pharmaceutical drugs are specialized medications used to treat various eye conditions and diseases such as glaucoma, dry eye syndrome, infections, and inflammatory disorders. These drugs are formulated to be administered directly into the eye, ensuring targeted therapy with minimal systemic exposure, which can lead to reduced side effects. The range of ophthalmic drugs includes antibiotics, antifungal, anti-inflammatory agents, and treatments for chronic conditions like age-related macular degeneration (AMD) and diabetic retinopathy. With the rising incidence of eye-related ailments globally, these drugs play a critical role in preserving vision and improving the quality of life for patients suffering from ocular diseases.

How Are Advances in Medical Research Shaping the Ophthalmic Drugs Sector?

Advancements in medical research have significantly influenced the development of new and more effective ophthalmic drugs. Recent breakthroughs in understanding the pathophysiology of major eye diseases have led to the innovation of drugs that target specific molecular pathways involved in these conditions. For example, anti-VEGF (Vascular Endothelial Growth Factor) therapy has revolutionized the treatment of diseases like AMD and diabetic macular edema by inhibiting the growth of abnormal blood vessels in the retina. Additionally, advancements in drug delivery technology, such as sustained release implants and nanotechnology-based systems, have improved the efficacy of treatments by enhancing drug absorption and prolonging the duration of action, which is particularly beneficial for chronic diseases that require long-term management.

What Trends Are Driving the Ophthalmic Pharmaceutical Drugs Industry?

Several key trends are driving the ophthalmic pharmaceutical drugs industry. An aging global population is a major factor, as older individuals are at a higher risk for developing many types of eye diseases, including glaucoma and AMD. This demographic shift is increasing the demand for ophthalmic treatments and driving growth in the market. Furthermore, there is an increasing preference for minimally invasive treatments, which has spurred the development of advanced drug delivery systems that offer alternatives to traditional surgeries. The rise in prevalence of diabetes worldwide has also escalated the incidence of diabetic retinopathy, prompting a greater need for effective therapeutic interventions. Additionally, increased awareness and improved diagnostic techniques are enabling earlier detection and treatment of eye conditions, further propelling the demand for ophthalmic drugs.

What Drives the Growth of the Ophthalmic Pharmaceutical Drugs Market?

The growth in the ophthalmic pharmaceutical drugs market is driven by several factors, including technological advancements in drug development and delivery systems that enhance treatment efficacy and patient compliance. The expanding geriatric population globally, which is more susceptible to chronic eye conditions, significantly contributes to the increasing demand for ophthalmic medications. Moreover, the global increase in chronic diseases such as diabetes, which are often associated with serious eye complications, also boosts the market growth. Consumer behavior is shifting towards preferring advanced, less invasive treatment options that offer quicker recovery and fewer side effects, which in turn drives the adoption of innovative ophthalmic drugs. Lastly, governmental and non-governmental efforts to raise awareness about eye health and improve accessibility to ophthalmic treatments play crucial roles in the market expansion, ensuring a sustained demand for these vital medications.

SCOPE OF STUDY:

The report analyzes the Ophthalmic Pharmaceutical Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy, Other Drug Classes); Type (Prescription Drugs, Over-the-Counter Drugs)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • Allergan PLC
  • Bayer AG
  • F. Hoffmann-La Roche AG
  • Johnson and Johnson Vision Care Inc
  • Kyowa Kirin Co., Ltd
  • Novartis International AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Santen Pharmaceuticals Co., Ltd.
  • Shire PLC

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
    • Global Economic Update
    • Ophthalmic Pharmaceutical Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advances in Drug Delivery Systems Propel Growth in Ophthalmic Pharmaceutical Drugs Market
    • Increasing Prevalence of Eye Disorders Expands Addressable Market Opportunity
    • Technological Innovations in Formulations Generate Demand for Advanced Ophthalmic Drugs
    • Growth in Geriatric Population Drives Adoption of Ophthalmic Pharmaceuticals
    • Rising Awareness of Eye Health Strengthens Business Case for Preventative Treatments
    • Adoption of Biologics and Biosimilars Spurs Growth in Ophthalmic Drug Market
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Ophthalmic Pharmaceutical Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Ophthalmic Pharmaceutical Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Anti-VEGF Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Anti-VEGF Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Anti-VEGF Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Anti-Glaucoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Anti-Glaucoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Anti-Glaucoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Anti-Inflammatory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Anti-Inflammatory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Anti-Inflammatory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Anti-Allergy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Anti-Allergy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Anti-Allergy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Prescription Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Prescription Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Prescription Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Over-the-Counter Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Over-the-Counter Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Over-the-Counter Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • JAPAN
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • CHINA
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • EUROPE
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Ophthalmic Pharmaceutical Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • FRANCE
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • GERMANY
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Ophthalmic Pharmaceutical Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • INDIA
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Ophthalmic Pharmaceutical Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Ophthalmic Pharmaceutical Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • AFRICA
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030

IV. COMPETITION